# Pioglitazone

## Glitis 30mg

| TAH Drug Code      | [OGLIT3](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OGLIT3)                                                                                                                                                                                                                                                                                               |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Type 2 diabetes mellitus.                                                                                                                                                                                                                                                                                                                                              |
| Dosing             | Type 2 diabetes mellitus: Initial 15 or 30 mg orally once daily; titrate in 15-mg increments; MAX 45 mg daily.                                                                                                                                                                                                                                                         |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                          |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                          |
| Contraindications  | New York Heart Association Class III or IV heart failure. Hypersensitivity to pioglitazone hydrochloride or any other component of the product.                                                                                                                                                                                                                        |
| Adverse Effects    | Common: Edema (4.8-15.3%), Weight gain, Anemia (<or equal to 2%), Fracture of bone (5.1%), Myalgia (5.4%), Headache (9.1%), Pharyngitis (5.1%), Sinusitis (6.3%), Upper respiratory infection (13.2%). Serious: Congestive heart failure, ALT/SGPT level raised (0.3%), Liver failure, Macular edema due to diabetes mellitus, Bladder cancer (0.23-0.54%), Pneumonia. |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                            |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                          |
| More Info          | [UpToDate](https://www.uptodate.com/contents/pioglitazone-drug-information)                                                                                                                                                                                                                                                                                            |

